US 12,071,392 B2
Aminoadamantyl nitrate compounds and their use to treat CNS disorders
Cyrus K. Becker, Pleasanton, CA (US); Meenakshi S. Venkatraman, Fremont, CA (US); Xiaoming Zhang, Sunnyvale, CA (US); James W. Larrick, Sunnyvale, CA (US); and Stuart Arthur Lipton, Rancho Santa Fe, CA (US)
Assigned to Panorama Research, Inc., Sunnyvale, CA (US)
Filed by Panorama Research, Inc., Sunnyvale, CA (US)
Filed on Sep. 19, 2022, as Appl. No. 17/947,817.
Application 17/947,817 is a continuation of application No. 16/766,357, granted, now 11,447,442, issued on Sep. 20, 2022, previously published as PCT/US2018/061981, filed on Nov. 20, 2018.
Claims priority of provisional application 62/590,179, filed on Nov. 22, 2017.
Prior Publication US 2023/0130425 A1, Apr. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 219/24 (2006.01); A61K 31/16 (2006.01); A61P 11/00 (2006.01); A61P 25/00 (2006.01); C07C 211/19 (2006.01); C07C 211/27 (2006.01); C07C 217/60 (2006.01); C07C 219/32 (2006.01)
CPC C07C 219/24 (2013.01) [A61K 31/16 (2013.01); A61P 11/00 (2018.01); A61P 25/00 (2018.01); C07C 211/19 (2013.01); C07C 211/27 (2013.01); C07C 217/60 (2013.01); C07C 219/32 (2013.01); C07C 2603/74 (2017.05)] 17 Claims
OG exemplary drawing
 
1. A method of treating a central nervous system (CNS) disorder, comprising administering a therapeutically effective amount of a compound of Formula I, wherein Formula I is:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof; and
wherein the CNS disorder is associated with excitotoxicity due to excessive extrasynaptic glutamate.